Lehmann et al. showed that AR-positive TNBC frequently showed activating mutations in PIK3CA or pAKT, suggesting a tumor-promoting effect, but the possibility of the dual inhibition of PI3K and AR as a treatment strategy [89]. This evidence concerns the gene AR and neoplasm.